Diagnosis and clinical severity markers of bullous pemphigoid by Schmidt, Enno & Zillikens, Detlef
Diagnosis and clinical severity markers of bullous pemphigoid
Enno Schmidt* and Detlef Zillikens
Address: Department of Dermatology, University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany
*Corresponding author: Enno Schmidt (enno.schmidt@uk-sh.den)
F1000 Medicine Reports 2009, 1:15 (doi: 10.3410/M1-15)
The electronic version of this article is the complete one and can be found at: http://F1000.com/Reports/Medicine/content/1/15
Abstract
The use of a broad spectrum of novel detection systems for autoantibodies to the basement
membrane proteins BP180 and BP230 has greatly facilitated the diagnosis of bullous pemphigoid,
which most likely explains its increasing incidence in central Europe. Because the pathogenic
relevance of antibodies to human BP180 has been convincingly shown both in vitro and in vivo,
repeated testing for these antibodies appears to be helpful in guiding treatment decisions during the
course of the disease.
Introduction and context
Bullous pemphigoid (BP) is the most frequent auto-
immune bullous disorder and is clinically character-
ized by tense blisters and crusts on erythematous or
apparently uninvolved skin. Direct immunofluores-
cence (IF) microscopy of a perilesional skin biopsy that
typically reveals linear deposits of complement com-
ponent 3 (C3) and/or immunoglobulin G (IgG) at the
basal membrane zone (BMZ) is still the diagnostic
gold standard. The most sensitive substrate for screen-
ing of serum autoantibodies in subepidermal blistering
autoimmune diseases is 1 molar sodium chloride (1 M
NaCl) split human skin. In BP, the circulating IgG
autoantibodies label the epidermal side of the artificial
split. These autoantibodies are directed against two
hemidesmosomal proteins, BP180 and BP230 [1,2].
BP180, also known as type XVII collagen or BP antigen
2, is a transmembrane glycoprotein of about 1500
amino acids which ultrastructurally spans the lamina
lucida before kinking back from the lamina densa to
the lamina lucida. In contrast, BP230 is an intracellular
constituent of the hemidesmosomal plaque and
belongs to the plakin family of proteins. In recent
years, analysis of the fine specificities of various
isotypes of autoantibodies against the two target
antigens has led to both better diagnostic tools and
new insights into the pathogenicity of autoantibodies
in BP.
Recent advances
Diagnosis of bullous pemphigoid
For more than a decade, B-cell epitopes have been
known to be unequally distributed on BP180 in BP. The
extracellular portion of the 16th non-collagenous
(NC16A) domain was shown to be recognized by
about 80% of BP sera [3]. It then became obvious that
the majority of BP patients also raise antibodies against
epitopes outside the NC16A domain [4–9]. Interestingly,
IgG reactivity with C-terminal epitopes appeared to be
associated with the presence of both skin and mucosal
lesions [6–8] whereas the intracellular domain was
preferentially targeted at an early clinical stage [8].
Testing for anti-BP180 antibodies outside the NC16A
domain therefore is required in those patients unreactive
with the immunodominant domain and has been
included in our routine work-up. Most recently, the
extent of phosphorylation of BP180 was shown to be
important for binding of antibodies to its ectodomain
[10]. Because antibodies raised against the murine
homolog to the NC16A domain, expressed in Escherichia
coli, induce subepidermal blisters when injected into
neonatal mice, the relevance of phosphoepitopes on
BP180 needs to be determined.
The other major target antigen in BP, BP230, is
recognized in between 60 and 70% of patients by
enzyme-linked immunosorbent assay (ELISA)
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distributed but preferentially localize to the globular
C-terminal domain of BP230 that mediates interaction
with keratin filaments and is targeted by about 80% of
BP230-reactive BP sera [9,13,14]. Interestingly, reactivity
to BP230 was predominantly found in patients with
limited BP, and only less than 5% of BP sera exclusively
recognized BP230 [4]. By the combined use of detection
systems for anti-BP180 and anti-BP230 antibodies, all 49
BP sera were reactive in a recent multicenter prospective
study [9].
The novel diagnostic assays have greatly facilitated the
diagnosis of BP (Figure 1), which may explain the
increased incidence of BP that was recently observed in
a prospective study with patients from a well-defined
region, Lower Franconia in Germany. Compared with a
study of the same region 10 years earlier, the incidence
of BP has increased from 6.6 to 13.4 new cases per
million per year [15,16]. An even higher incidence
(including all subepidermal bullous diseases) of 43 new
cases per million per year, which has increased almost
fivefold within the last 10 years, was recently reported in
the UK [17]. The data, however, were retrieved from a
database for general practitioners and have been
challenged by the report that in St. John's Institute of
Dermatology, London, the diagnosis of BP, based on
direct IF microscopy, has not increased within the last
decade [18].
Whereas IgG reactivity to BP180 has been studied
intensively, the importance of BP180-specific antibodies
of the IgA and IgE isotypes has been highlighted only
recently. Indeed, the majority of BP sera contain IgA
antibodies to BP180 and most sera of patientswith linear
IgA disease raise IgG anti-BP180 antibodies in addition
to IgA reactivity [19]. There appears to be a spectrum of
the autoimmune response against BP180, ranging from
pure IgG to pure IgA reactivity, with mixtures in between.
This hypothesis is supported by the observation in
Uganda that younger patients with BP/linear IgA disease
were more likely to develop IgA anti-BMZ antibodies
whereas older patients tended to raise IgG autoantibo-
dies [20]. IgE reactivity against BP180 has been reported
in 30 to 95% of BP patients [21–25]. The majority of sera
contain IgE reactivity to the NC16A domain, and IgE
antibodies to the intracellular domain of BP180 have
also been detected recently [23,25].
In addition to reactivity against BP180 and BP230,
antibodies to the a6 chain of a6b4 integrin and laminin
332, also known as laminin 5, have been reported in
50% and 40% of BP patients, respectively [26,27]. The
relevance of these findings is elusive and both findings
await confirmation. A more recent report demonstrates
that the detection of antibodies to laminin 332 is rather
uncommon in BP [28].
Figure 1. Diagnostic pathway in bullous pemphigoid (BP)
Direct immunofluorescence (IF) microscopy of a perilesional biopsy is the
gold standard for the diagnosis of BP and differentiates subepidermal
blistering autoimmune diseases from pemphigus. By indirect IF microscopy
on 1 M NaCl spilt human skin, BP patients' sera are screened for anti-basal
membrane zone (BMZ) autoantibodies. Whereas sera from patients with
epidermolysis bullosa acquisita, anti-laminin 332 mucous membrane
pemphigoid, and anti-p200 pemphigoid label the dermal side of the artificial
split, sera of BP patients bind to the blister roof. Anti-BP180 antibodies can
be detected by BP180 NC16A-specific enzyme-linked immunosorbent assay
(ELISA), Western blotting with conditioned concentrated medium of
cultured HaCaT cells, which detects reactivity against LAD-1 (linear IgA
disease antigen 1) that corresponds to the cell-derived ectodomain of
BP180, and Western blotting with various other recombinant fragments
of BP180. Since four different entities are associated with IgG antibodies
to BP180, the clinical phenotype determines the final diagnosis. When no
BP180 reactivity is found, sera are assayed for BP230-specific antibodies
that, only in conjunction with a positive direct IF microscopy and compatible
clinical features support the diagnosis of BP. In case of epidermal binding by
indirect IF microscopy and failure to detect IgG reactivity to both BP180 and
BP230, testing for antibodies against a6b4 integrin is recommended (for
example, by Western blotting of keratinocyte extract) [44]. The shaded
boxes represent commercially available test systems. NC16A, the
extracellular portion of the 16th noncollagenous (domain).
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The first evidence for a pathogenic role of human
antibodies to human BP180 came from the observation
that levels of circulating antibodies to the NC16A
domain correlate with disease activity in BP patients
[29]. This notion has been corroborated in different
patient populations within recent years [30–34]. Thus,
the NC16A domain appears to be an important target for
monitoring circulating autoantibody levels and for
guiding treatment decisions; for example, the reduction
of the corticosteroid dose during the course of the
disease. By the use of an NC16A tetramer, a second
commercially available ELISA that is a highly sensitive
and specific tool for the detection of serum antibodies in
BP has been established [35]. Autoantibody levels to a
C-terminal stretch of BP180 have subsequently been
shown to parallel clinical activity in BP [9].
The pathogenic relevance of human antibodies to
human BP180 had previously been suggested in vitro
when the incubation of cultured human keratinocytes
and cryosections of human skin with BP IgG resulted in
increased mRNA levels followed by the release of
proinflammatory cytokines or dermal-epidermal separa-
tion, respectively [36,37]. Most recently, a decrease of
cell-surface BP180 that led to weakened cell attachment
has been observed in response to the incubation of
cultured human keratinocytes with anti-BP180 antibo-
dies [38]. In addition, in vivo data have been provided by
Nishie et al. [39], who induced BP-like skin lesions by
injection of IgG from BP patients into Col17 knockout
mice rescued by the human ortholog.
The importance of IgE autoantibodies to BP180 NC16A
has been highlighted by demonstrating a correlation
between clinical activity and IgE NC16A-specific circulat-
ing antibodies that were detected in 60% of BP patients
[21]. Subsequently, IgE antibodies directed against this
domain were linked to both a greater extent of skin
lesions and a longer time period until remission was
induced [23]. These observations have been substan-
tiated in two passive-transfer mouse models. The
injection of BP IgE or an IgE-producing hybridoma
against the BP180 ectodomain into human skin grafted
on to athymic nude mice or SCID (severe combined
immunodeficiency disease) mice, respectively, resulted
in an erythematous itchy plaque, which showed dermal-
epidermal separation by histopathology [40,41].
Whether measurement of IgE anti-BP180 NC16A anti-
bodies will be included in the routine analysis of BP sera
needs to be addressed in future studies.
Whereas the pathogenic relevance of antibodies to
BP180 is well established, the role of anti-BP230
reactivity is less clear. Serum levels of anti-BP230
antibodies repeatedly failed to parallel disease activity
in BP patients [4,9,12]. In addition, experimental
evidence for the pathogenicity of anti-BP230 antibodies
is inconclusive and needs further exploration.
Implications for clinical practice
Direct IF microscopy of a perilesional biopsy is still
regarded as the gold standard in the diagnosis of BP.
A large body of evidence, however, has been collected
supporting the notion that, in a large majority of BP
patients, the disease can be diagnosed serologically by
the detection of BP180 NC16A-specific autoantibodies.
Rarely, anti-BP180 antibodies have also been found in
patients with pruritic disorders, diabetes mellitus, or
dementia, even when there have been no associated
clinical signs of BP and direct IF microscopy has been
negative [42,43]. Usually, however, in patients with
clinical lesions typical for BP, the detection of antibodies
to BP180 NC16A suffices to establish the diagnosis of
BP, whereas serum antibodies to BP230 require a
positive direct IF microscopy to diagnose BP. Finally,
based on our personal experience, repeated testing for
serum anti-BP180 NC16A antibodies during the course
of the disease may be a helpful guide for treatment
decisions.
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